Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management
(Heart failure) :
In the SURPASS-2 trial, Mounjaro 15 mg achieved nearly twice the weight loss of Ozempic 1 mg in people with type 2 diabetes
The gut microbial metabolite trimethylamine-N-oxide is present in human cerebrospinal fluid
US$ 23.04
US$ 20.96
US$ 27.66
US$ 24.18
US$ 22.17
US$ 29.51
US$ 20.67
